In a significant case before the U.S. Supreme Court, oral arguments have been heard regarding the FDA’s approval and deregulation of the abortion pill mifepristone. The Alliance for Hippocratic Medicine (AHM), representing pro-life medical groups, has challenged the FDA’s decision, particularly regarding prescribing the drug without an in-person doctor’s visit and allowing mail distribution. Justices expressed concerns over safety issues but questioned whether AHM had the legal standing to sue. The outcome of this case, expected in June, could have far-reaching implications.
Supreme Court Questions FDA on Mifepristone Safety in Landmark Abortion Case, US
Date:
Updated: [falahcoin_post_modified_date]